日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)

Talimogene laherparepvec 新辅助治疗在皮肤基底细胞癌中的疗效和耐受性:一项 II 期试验(NeoBCC 试验)

Julia Maria Ressler ,Maud Plaschka ,Rita Silmbrod ,Victoria Bachmayr ,Lisa Ellen Shaw ,Thomas Silly ,Nina Zila ,Andreas Stepan ,Anna Kusienicka ,Philipp Tschandl ,Julia Tittes ,Florian Roka ,Werner Haslik ,Peter Petzelbauer ,Franz Koenig ,Rainer Kunstfeld ,Matthias Farlik ,Florian Halbritter ,Wolfgang Weninger ,Christoph Hoeller

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma

DNA甲基化特征与转移性黑色素瘤对免疫检查点抑制剂的反应相关

Ressler, Julia Maria; Tomasich, Erwin; Hatziioannou, Teresa; Ringl, Helmut; Heller, Gerwin; Silmbrod, Rita; Gottmann, Lynn; Starzer, Angelika Martina; Zila, Nina; Tschandl, Philipp; Hoeller, Christoph; Preusser, Matthias; Berghoff, Anna Sophie

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

在奥地利、瑞士和德国的医疗中心,talimogene laherparepvec (T-VEC) 在黑色素瘤患者中的实际应用

Ressler, Julia Maria; Karasek, Matthias; Koch, Lukas; Silmbrod, Rita; Mangana, Joanna; Latifyan, Sofiya; Aedo-Lopez, Veronica; Kehrer, Helmut; Weihsengruber, Felix; Koelblinger, Peter; Posch, Christian; Kofler, Julian; Michielin, Olivier; Richtig, Erika; Hafner, Christine; Hoeller, Christoph

Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report

晚期黑色素瘤患者接受Talimogene laherparepvec (T-VEC) 治疗后获得完全缓解:一例心脏和肾脏移植患者的病例报告

Ressler, J; Silmbrod, R; Stepan, A; Tuchmann, F; Cicha, A; Uyanik-Ünal, K; Hoeller, C